Who Owns Caremark?

• Parent Company: CVS Health
• Ownership Type: Wholly owned
• Acquisition Year: 2007
• Company Type: Publicly Traded
• Stock Ticker: NYSE: CVS

• Founded: 1993
• Founders: Medco Health Solutions (spin-off)
• Acquired by CVS Health: 2007

• Founded: 1963
• Headquarters: Woonsocket, Rhode Island, USA
• Company Type: Publicly Traded
• Stock: NYSE: CVS
• Revenue: $402.1 billion (FY2025)
• Employees: Approximately 300,000

Visit CVS Health website

• Headquarters: Woonsocket, Rhode Island, USA
• Manufacturing / Operations: United States

Caremark operates within CVS Health's comprehensive healthcare sustainability framework, implementing environmental and ethical initiatives that align with the healthcare company's commitment to responsible pharmacy benefits management and healthcare cost containment. As one of the largest pharmacy benefit managers in the United States, Caremark plays a critical role in the healthcare system's sustainability and ethical practices.

Healthcare Cost Containment: Caremark's core sustainability mission focuses on reducing healthcare costs through effective pharmacy benefits management. The PBM negotiates rebates with pharmaceutical manufacturers, implements formulary management strategies, and utilizes generic substitution programs to control prescription drug costs for health plans and patients.

Medication Adherence Programs: Caremark implements comprehensive medication adherence programs that improve patient health outcomes while reducing overall healthcare costs. These programs include refill reminders, clinical counseling, and medication therapy management that contribute to long-term healthcare system sustainability.

Environmental Impact Reduction: Through mail-order pharmacy services and centralized distribution, Caremark reduces the environmental footprint of prescription fulfillment compared to traditional retail pharmacy models. The division's efficient logistics networks minimize transportation emissions and packaging waste.

Data-Driven Healthcare Decision Making: Caremark utilizes advanced analytics and real-time data to support evidence-based formulary decisions and cost-effective treatment options. This data-driven approach promotes sustainable healthcare spending while maintaining quality patient care.

Generic and Biosimilar Promotion: Caremark actively promotes the use of generic medications and biosimilars when appropriate, significantly reducing healthcare costs while maintaining therapeutic effectiveness. This approach supports both economic and environmental sustainability in healthcare delivery.

Ethical Business Practices: As part of CVS Health, Caremark operates under strict ethical guidelines and compliance programs, including adherence to HIPAA privacy regulations, anti-kickback statutes, and other healthcare industry ethical standards designed to protect patients and ensure fair business practices.

Caremark has received significant recognition for its leadership in pharmacy benefits management, innovation in healthcare cost management, and contributions to the healthcare industry, establishing itself as one of the most influential PBMs in the United States.

Market Leadership Recognition: Caremark has been acknowledged as one of the "Big Three" PBMs controlling approximately 80% of the U.S. prescription claims market. In 2024, Caremark maintained a 27% market share of total prescription claims, demonstrating its dominant position in the pharmacy benefits management industry.

Healthcare Cost Management Achievement: The division has been recognized for its effectiveness in controlling prescription drug costs through formulary management, rebate negotiations, and generic substitution programs. Caremark's ability to deliver cost savings to health plans and patients has been acknowledged as driving value-based healthcare.

Innovation in Pharmacy Services: Caremark has been acknowledged for developing innovative pharmacy benefits management solutions, including advanced clinical programs, digital health tools, and personalized medication management services that improve patient outcomes while reducing costs.

Integration Excellence: Since the 2007 CVS Health acquisition, Caremark has been recognized for successfully integrating pharmacy benefits management with retail pharmacy operations, creating a comprehensive healthcare model that has been acknowledged as industry-leading.

Technology and Analytics Leadership: Caremark's use of advanced analytics, artificial intelligence, and data-driven decision making has been recognized as setting industry standards for PBM operations and healthcare cost management.

Regulatory Compliance Recognition: The division has been acknowledged for maintaining strict compliance with complex healthcare regulations, including HIPAA, anti-kickback statutes, and Medicare Part D requirements, while operating in a highly regulated environment.

Patient Access Improvement: Caremark has been recognized for expanding patient access to affordable medications through formulary management, specialty pharmacy services, and innovative delivery models that improve medication adherence and health outcomes.

Caremark has faced significant scrutiny and controversies related to its business practices, market dominance, and role in prescription drug pricing, reflecting broader challenges facing the pharmacy benefits management industry.

Formulary Tier and Rebate Controversies: Caremark has been criticized for designing drug formularies that incentivize high list-price drugs with substantial rebates over cheaper generic alternatives. Critics argue this practice can keep drug prices artificially high, as manufacturers set launch prices anticipating PBM rebate demands.

Lack of Transparency Issues: Caremark's complex and confidential contracts have drawn criticism for lack of transparency regarding rebate amounts, fees, and cost savings. Health plans and policymakers have expressed difficulty assessing whether Caremark's practices truly benefit clients or primarily enrich the PBM.

Spread Pricing and DIR Fee Controversies: The division's use of spread pricing and Direct and Indirect Remuneration (DIR) fees has been highly controversial, particularly in Medicare Part D. These retroactive fees have been criticized for siphoning money from pharmacies and reducing reimbursements over time.

Network Exclusion Allegations: Caremark has faced allegations of excluding independent pharmacies from lucrative networks while favoring CVS retail locations and affiliated pharmacies. Critics argue this practice harms independent pharmacies and reduces competition in the pharmacy market.

Vertical Integration Conflicts: As part of CVS Health, Caremark faces ongoing criticism for potential conflicts of interest in steering patients to CVS pharmacies and CVS specialty pharmacy services. Congressional hearings have examined whether these vertical integrations harm competition and increase costs.

Antitrust and Regulatory Scrutiny: Caremark is currently subject to Federal Trade Commission investigation regarding alleged inflation of insulin costs, along with other major PBMs. The division faces ongoing regulatory pressure regarding its market dominance and business practices.

Independent Pharmacy Lawsuits: Caremark has been involved in lawsuits with independent pharmacies seeking access to its PBM networks. These cases highlight tensions between Caremark's network management practices and independent pharmacy sustainability.

Healthcare Cost Debate: Despite Caremark's role in cost containment, the division faces ongoing debate about whether PBM practices ultimately reduce or increase overall healthcare costs. Critics argue that PBM profits and complex rebate structures may undermine cost-saving intentions.